After 28 days, the mice receiving the IL‐2 and anti‐CTLA4 Ab‐loaded aAPCs demonstrated significantly smaller tumor size as well as increased survival, compared to the groups being treated with IL‐2 or anti‐CTLA4 Ab‐loaded aAPCs. The gene discussed is CTLA4; the disease is neoplasm.